Search clinical trials for: Anlotinib

Total 1410 results

Georgetown University

Completed

Nilotinib in Cognitively Impaired Parkinson Disease Patients 001

Parkinson's Disease | Parkinson's Disease Dementia | Diffuse Lewy Body Disease

United States
Zhejiang Cancer Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.; Innovent Biologics (Suzhou)...

Unknown

The Efficacy and Safety of Antinib Hydrochloride Combined With Sindilumab in Advanced NSCLC Patients

NSCLC

China
Third Military Medical University

Recruiting

Toripalimab Combined With Anlotinib, Etoposide and Platinum in the Treatment of Extensive-stage Small Cell Lung Cancer

Small Cell Lung Cancer | Lung Cancer | SCLC, Extensive Stage

China
Novartis Pharmaceuticals

Completed

An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment (MACS0999)

Chronic Myelogenous Leukemia

United States, Canada
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

A Clinical Trial to Evaluate TQB2858 Injection Combined With Anlotinib Hydrochloride Capsule in the Treatment of Recurrent or Metastatic Advanced Endometrial Carcinoma

Endometrial Carcinoma

China
Fudan University

Not yet recruiting

Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC

Small Cell Lung Cancer Recurrent

China
Jill M Kolesar
National Cancer Institute (NCI); Novartis

Recruiting

Nilotinib Plus Dabrafenib/Trametinib in Metastatic Melanoma

Metastatic Melanoma | BRAF Gene Mutation

United States
Novartis Pharmaceuticals

Completed

Nilotinib for Patients With Chronic Myeloid Leukemia in First Line and Any Subsequent Line (NOFRETETE)

Chronic Myeloid Leukemia

Germany
Hospital for Special Surgery, New York
Novartis Pharmaceuticals; Rudolph Rupert Scleroderma Program

Completed

Nilotinib in the Treatment of Systemic Sclerosis

Systemic Sclerosis

United States
Novartis Pharmaceuticals

Completed

Pharmacokinetics of Nilotinib in Subjects With Impaired Hepatic Function and Healthy Subjects With Normal Hepatic Function

Healthy

United States
Jinming Yu

Recruiting

A Phase Ib Study of TQB2450 Combined With Anlotinib in Patients With Limited Stage Small Cell Lung Cancer After First-line Radiotherapy and Chemotherapy

Limited Stage Small Cell Lung Cancer | Not Progressed After First-line Chemoradiotherapy

China
Di Wu

Not yet recruiting

Study of Anlotinib Hydrochloride and Toripalimab in Subjects With Unresectable or Metastatic Undifferentiated Pleomorphic Sarcoma

Undifferentiated Pleomorphic Sarcoma | Soft Tissue Sarcomas

China
Advenchen Laboratories, LLC

Terminated

Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001) (AL3818)

Cervical Cancer | Ovarian Cancer | Endometrial Cancer

United States
Cancer Institute and Hospital, Chinese Academy...

Recruiting

TQB2450 Combined With Anlotinib Hydrochloride in the Perioperative Treatment of Hepatocellular Carcinoma Hydrochloride Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With a High Risk of Recurrence or Metastasis

Patients With Resectable Hepatocellular Carcinoma Who Are at High Risk of Recurrence or Metastasi

China
Novartis Pharmaceuticals

Completed

Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline. (NILOdeepR)

Chronic Myeloid Leukemia

Germany
Novartis Pharmaceuticals

Completed

A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML. (ENESTPath)

Philadelphia Chromosome Positive (PH+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

Germany, Belgium, France, Italy, Spain, Hungary, Austria, Sweden, Bulgaria, Denmark, Greece, Slovenia, United Kingdom, Czechia, Romania, Serbia, Slovakia, Portugal, Finland, Norway, Poland
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Completed

To Evaluate the Effect of Food on the Pharmacokinetic Characteristics of Alkotinib Capsules in Healthy Subjects

NSCLC

China
Seoul National University Hospital
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Nilotinib in CML-CP (ENESTKorea)

Chronic Myeloid Leukemia, Chronic Phase
Indiana University
Novartis

Completed

Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas

Neurofibromatosis | NF1 | Neurofibromas

United States
Sun Yat-sen University

Withdrawn

Evaluating Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung Cancer

Efficacy and Safety | Locally Advanced Non-small Cell Lung Cancer

China
Zhongshan People's Hospital, Guangdong, China

Recruiting

Anrotinib and Tirelizumab in First-line Treatment of RM-NPC

Nasopharyngeal Carcinoma

China
Shanghai Chest Hospital

Unknown

Anlotinib Plus Etoposide and Carboplatin as First-line Treatment for Extensive-stage Small Cell Lung Cancer

SCLC | Anlotinib

China
Gruppo Italiano Trapianto di Midollo Osseo

Completed

Phase I/II for Safety and Efficacy of Nilotinib in a Population Steroid-refractory/or Steroid-dependent cGVHD (Nilo-cGVHD)

Chronic Graft Versus Host Disease

Israel, Italy
Georgetown University

Unknown

Nilotinib in Huntington's Disease (Tasigna HD)

Huntington Disease

United States
National Cancer Institute (NCI)
University of Chicago; City of Hope Medical Center; University of Southern California and other collaborators

Completed

Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...

Non Small Cell Lung Carcinoma

United States
Zhejiang Cancer Hospital

Recruiting

A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Anlotinib as Maintenance Therapy for ES-SCLC

Extensive Stage Small Cell Lung Cancer

China
Rong Tao

Recruiting

Sintilimab, Pegaspargase and Anlotinib for Stage IV Natural Killer /T-cell Lymphoma

Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type

China
The First Affiliated Hospital, Guangzhou University...

Not yet recruiting

A Single-arm Pilot Study of Tislelizumab Combined With Anlotinib in Patients With Advanced NSCLC With Driver-negative After Progression to Immunotherapy

Advanced NSCLC
Dana-Farber Cancer Institute
Massachusetts General Hospital; Novartis; Beth Israel Deaconess Medical Center; Brigham and Women's Hospital

Completed

Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma

Melanoma | Acral Melanoma | Mucosal Lentiginous Melanoma

United States
Weill Medical College of Cornell University
Novartis Pharmaceuticals

Completed

Stem Cell Monitoring for CML Patients Undergoing Nilotinib Therapy

Chronic Myeloid Leukemia

United States
Novartis Pharmaceuticals

Completed

Study of Nilotinib as First Line Treatment in Philadelphia Chromosome Positive(Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

Chronic Myelogenous Leukemia

Turkey
Stanford University
Novartis

Completed

Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease

Lymphoma, Non-Hodgkin | Lymphoma, T-Cell, Peripheral | Bone Marrow Transplant Failure

United States, Canada
Rony Schaffel

Terminated

Nilotinib With Chemotherapy for the Treatment of Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (ALLPhi)

Acute Lymphoblastic Leukemia | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
M.D. Anderson Cancer Center
Novartis

Withdrawn

Tasigna Neoadjuvant Gastrointestinal Stromal Tumor (GIST)

Gastrointestinal Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer.

Colorectal Cancer

China
Shandong Cancer Hospital and Institute

Terminated

A Trial of Anlotinib Combined With Concurrent Chemoradiotherapy in Patients With Unresectable Stage III Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Pfizer

Completed

Trial Of Erlotinib With Or Without PF-3512676 In Advanced Non Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States
The First Affiliated Hospital of Guangzhou Medical...

Unknown

A Study of Neoadjuvant Chemotherapy Plus Anlotinib in Stage III(N2) Non-small-cell Lung Cancer

Stage III Non-small-cell Lung Cancer

China
Fox Chase Cancer Center
Millennium Pharmaceuticals, Inc.

Terminated

Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Recurrent

United States
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules for First-line Treatment of Advanced Hepatocellular Carcinoma (HCC).

Advanced Hepatocellular Carcinoma

China
Shanghai Chest Hospital

Unknown

Combination Therapy of Sintilimab and Anlotinib as a First-line Treatment in Advanced NSCLC (SUNRISE)

Carcinoma | Non-small Cell Lung Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer (ETER701)

Extensive Small Cell Lung Cancer

China
Peking University People's Hospital
Hunan Cancer Hospital; Peking University Cancer Hospital & Institute; Peking... and other collaborators

Unknown

Anlotinib Hydrochloride Combined With Liposomal Doxorubicin in the Treatment of Locally Advanced or Metastatic Soft Tissue Sarcoma (ALTER-S001)

Sarcoma

China
Henan Cancer Hospital

Not yet recruiting

TQB2450 (PD-L1 Inhibitor) Plus Anlotinib Combined With Chemotherapy in the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma

Gastric Cancer | Adenocarcinoma of Esophagogastric Junction
AVEO Pharmaceuticals, Inc.
Biodesix, Inc.

Terminated

A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive Label (FOCAL)

Non-small Cell Lung Cancer

Korea, Republic of, United States, Australia, Taiwan, Singapore, Hong Kong, Italy
M.D. Anderson Cancer Center

Completed

An Umbrella, Modular Study Based on Epidermal Growth Factor Receptor (EGFR) Mutation Status

Advanced Cancers

United States
M.D. Anderson Cancer Center
Novartis

Completed

Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML)

Leukemia, Myelogenous, Chronic

United States
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer.

Advanced Squamous Non-Small Cell Lung Carcinoma

China
Xiaorong Dong

Unknown

Anlotinib In Combination With PD-1/L1 Inhibitor As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study

NSCLC | Anlotinib | PD-1/L1 Inhibitor
Peking Union Medical College Hospital

Unknown

Efficacy and Safety Study of Anlotinib With Pembrolizumab in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Non-small Cell Lung Cancer

NSCLC

China

3

Subscribe